Context: Thyroid dysgenesis (TD) is the leading cause of congenital hypothyroidism (CH). The etiology of TD remains unknown in ;90% of cases, the most common form being thyroid ectopia (TE) (48% to 61%).
C ongenital hypothyroidism (CH) is the endocrine disease with the highest frequency among newborns (1) . CH can result from the disruption of thyroid hormone synthesis [dyshormonogenesis; Online Mendelian Inheritance in Man (OMIM) 274400, 274500, 274600, 274700, 274800, 274900, 607200; 15% to 20%] or altered embryogenesis [thyroid dysgenesis (TD); OMIM 218700; 80% of cases] (1). Thyroid gland embryogenesis involves a coordinated spatial and temporal process and, when altered, can result in ectopic thyroid gland, hypoplasia, agenesis, or hemiagenesis (2) (3) (4) (5) .
TD, the leading cause of CH, is a complex group of developmental diseases, with only 2% to 3% of cases having mutations in PAX8, TSHR, FOXE1, NKX2-1, or NKX2-5. However, other genetic mechanisms may be involved; Thorwarth et al. verified that 8.75% of 80 patients with agenesis and hypoplasia had copy number variations in a different frequency (6) .
Ectopia (or ectopic thyroid) is the most common TD subtype (48% to 61% of cases) (2) and is characterized by the presence of thyroid tissue in locations other than the anterior pharynges, along with the normal migrating pathway of the thyroglossal duct. Animal models with disruption of the Foxe1 gene have this malformation. The phenotype of these animals varies from agenesis (50%) to ectopia (50%) (7) .
The aim of the current study was to search for candidate genes in hypothyroid children with thyroid ectopia (TE). We identified new and previously known DUOX2 mutations that segregate with the TE phenotype. DUOX2, which belongs to the NAD phosphate (NADPH) oxidase (NOX/ DUOX) family, is the leading hydrogen peroxide (H 2 O 2 ) source involved in the thyroperoxidase (TPO)-mediated iodide organification reaction that is necessary for thyroid hormone biosynthesis (8, 9) . We also demonstrated that some of these mutants impair DUOX2 reactive oxygen species generation.
Subjects and Methods

Patients
A cohort of 631 patients with CH were followed up by physicians from the Department of Pediatrics of Universidade Federal do Paraná (UFPR) in Curitiba, Brazil, and from the Departments of Pediatrics and Medicine of the Universidade Federal de São Paulo (UNIFESP) in São Paulo, Brazil. The diagnosis of CH was made by thyroid-stimulating hormone (TSH) and free/total thyroxine (T4) at the time of neonatal thyroid screening and after the confirmatory test in serum. When the children were 3 years old, to establish the cause of CH they underwent thyroid echography, scintigraphy, serum TSH analysis, and free/total T4 analysis ;30 days after interruption of levothyroxine. Among the 631 patients, 268 had a diagnosis of TD, 134 of whom were TE cases. We selected 44 TE cases who were not lost during follow-up (43 sporadic and 1 familial). The research ethics committees from UNIFESP (CEP/HSP 0237/11) and UFPR (CEP/HC 1158.006/2006-01) approved this work. All participants or the children's parents provided informed consent.
Whole-exome sequencing analysis
We used peripheral blood samples from patients with TE to extract total DNA to perform whole-exome sequencing (WES) and Sanger sequencing, as previously described (10 Sanger sequencing for mutation validation and additional cohort screening
We validated the variations identified through WES in the coding region of the DUOX2 gene by Sanger sequencing and then extended the analysis of all exons of the DUOX2 of the additional cohort of 41 patients with TE. We performed polymerase chain reaction amplification by using a precise flanking pair of primers designed by Primer3 Software (http:// bioinfo.ut.ee/primer3-0.4.0/; Supplemental Table 1) and Sanger sequencing as previously described (10) . We analyzed the sequences through the bioinformatic software CLC Main Workbench 6 (www.clcbio.com) and aligned them to the reference sequence provided by the National Center for Biotechnology Information (NG_009447.1).
Site-directed mutagenesis, transformation, and plasmid DNA isolation
We performed site-directed mutagenesis by using 25 ng of the NH2 terminal hemagglutinin (HA) epitope tag human DUOX2 (HA-DUOX2 pcDNA3), kindly provided by Dr. Xavier de Deken (Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Brussels, Belgium) as a template. We added 125 ng of high-performance liquid chromatographypurified primer pairs containing the desired mutations (Supplemental Table 2 ), 103 reaction buffer, deoxynucleotide triphosphate mix, and Pfu Ultra High-Fidelity DNA polymerase (2.5 U/mL), following the manufacturer's protocol (Agilent Technologies ® , Santa Clara, CA). After amplification and digestion of the parental methylated/hemimethylated DNA with DpnI (10 U/mL), we proceeded to transformation in DH5a-competent cells (Thermo Fisher Scientific, Carlsbad, CA) and selection with ampicillin (Thermo Fisher Scientific, Grand Island, NY). After overnight incubation of each bacterial colony in LB Broth Base (Thermo Fisher Scientific, Carlsbad, CA) with ampicillin, we extracted the plasmid DNA by using a PureLink Quick Plasmid MiniPrep Kit (Thermo Fisher Scientific, Lohne, Germany), following the manufacturer's recommendations. We screened the colonies through Sanger sequencing, and those with desired mutations were cultivated and submitted to MaxiPrep extraction (QIAfilter Plasmid Maxi Kit; Qiagen, Hilden, Germany) to provide sufficient plasmid DNA for functional studies.
Cell culture and transfection
We grew the HEK293 cells in Dulbecco's modified Eagle medium (high glucose; PAA, Thermo Fisher Scientific, Grand Island, NY) containing 10% (v/v) fetal calf serum and penicillin/ streptomycin (100 mg/mL; Life Technologies, Grand Island, NY). Primary human thyroid cells from normal thyroid tissue were cultured as previously described (14) . We transfected the cells with wild-type (WT) and mutated HA-DUOX2 pcDNA3, the NH2 terminal cMyc epitope tag human DUOXA2, and the COOH terminal cMyc epitope tag human DUOXA2 (cMyc-DUOXA2 pcDNA3), as described elsewhere (15) 
Western blot analysis
Cell extracts were solubilized in denaturing sample buffer (16) 
Flow cytofluorometry assay
For surface protein staining, cells were incubated with a rat anti-HA of high affinity (clone 3F10; Roche Diagnostics) for the NH2-terminal HA epitope tag human DUOX2 surface immunofluorescence staining. Fluorescence was assayed using a BD Accuri C6 Flow Cytometer (BD Biosciences ® , San Jose, CA). We determined the relative protein expression by calculating the differences in total fluorescence between the sample and an equalsized ratio of pcDNA3-DUOX2-and DUOXA2-transfected cells corresponding to 100%.
Immunofluorescence study
For staining of the NH2-terminal HA epitope tag human DUOX2 we incubated the cells with rat anti-HA clone 3F10 in tris buffered saline buffer containing 0.3% BSA. Alexa 488-conjugated antirat immunoglobulin G was used as the secondary antibody. After two washing steps in tris buffered saline with 0.1% Tween and staining with 4 0 ,6-diamidino-2-phenylindole (Life Technologies), we captured the fluorescent images with a confocal microscope (Leica DM IRE 2; PerkinElmer ® , Waltham, MA).
Results
Genotyping and mutation prediction analysis Through WES filtering analysis of three patients with congenital hypothyroidism with thyroid ectopia (CHTE), we confirmed the lack of mutations in genes related to TDs (NKX2-1, NKX2-5, FOXE1, PAX8, HHEX, and TSHR). However, we found a variation in the coding region of the DUOX2 gene, primarily related to thyroid dyshormonogenesis (TH) ( Table 1) , in one-third of the TE cases.
Patient 1 has a c.2428G.T substitution, creating a new premature stop codon in exon 19 (E810X). All three patients presented with high TSH levels at diagnosis and at the time of scintigraphy, with low or undetectable levels of T4 [ Table 1 , Fig. 1(a) ]. The WES findings are described in Supplemental Table 3 . We found no deleterious variations associated with the phenotype in other genes related to TH (SL5A5, TPO, SLC26A4, DUOX1, DUOXA2, and TG).
To expand the search for other alterations in the DUOX2 gene, we screened another 41 CHTE cases. We identified seven new (G201E, L264CfsX57, P609S, M650T, E810X, and M822V, and E1017G) and eight (P138L, D506N, H678R, R701Q, A728T, S965SfsX29, P982A, and S1067L) previously described variations ( Fig. 1 , Tables 1 and 2 ). In Table 1 we summarize all DUOX2 variations with MAF #1% or those already reported in patients with permanent, transient, or subclinical hypothyroidism, together with major clinical features. All variants were localized at the N-terminal domain of DUOX2 (i.e., ectodomain; P138L, G201E, L264CfsX57, and D506N), the first transmembrane domain (P609S), the intracellular loop containing the calcium-sensitive region of DUOX2 (M650T, H678R, R701Q, A728T, E810X, M822V, S965SfsX29, P982A, and E1017G), and the first extracellular loop (S1067L). These variants were identified in the DUOX2 coding region in one or more TE cases (Table 1) . ClustalOmega ® (EMBL-EBI, Cambridgeshire, UK) analysis showed that the variations are located at conserved sites of DUOX2 protein during evolution [ Fig. 1(b) ]. All children had high TSH levels at diagnosis and had been undergoing treatment with levothyroxine. On follow-up, they presented with permanent hypothyroidism and are still being followed by both UNIFESP and UFPR clinics.
In vitro functional analysis
Western blot analysis in reducing conditions detected all new DUOX2 mutants (G201E, P609S, M650T, and M822V) as a band of 185 kDa, except for the two mutants, L264CfsX57 and E810X, which led to the detection of truncated proteins at ;40 and ;120 kDa, Fig. 2(b) ], the absence of H 2 O 2 -generating activity [ Fig. 2(c)] , and a lack of targeting to the cell surface, evidenced by flow immune cytofluorometry and immunofluorescence microscopy [ Figs. 2(d-f) and 3(a) ]. This mutation significantly affected the levels of DUOXA2 expression, the maturation factor of DUOX2. This mutation completely abolished the shift in the electrophoretic mobility from 185 to 250 kDa, the DUOX2 oxidized form, which could covalently link DUOXA2 by disulfide bridge, affecting DUOXA2 expression [ Fig. 3(b) ]. Therefore, the G201E-DUOX2 mutant Abbreviations: 2nd, second-degree relative; 3rd, third-degree relative; After, dosage after scintigraphy; hm, homozygous; ht, heterozygous; NE, not specified; Sanger, Sanger sequencing; SL, sublingual ectopy; SM, submandibular ectopy; t, total. a Described in patients with permanent hypothyroidism.
b Described in patients with transient hypothyroidism.
c Described in patients with subclinical hypothyroidism. was unable to activate TPO, being functionally inactive [ Fig. 3(c) ]. The M822V-DUOX2 mutant conserved the biochemical characteristics of the WT, even in presence of the calcium ionophore ionomycin, and similar to the other mutants that are also active (P609S, M650T, and A728T).
Discussion
In this study, we demonstrated that DUOX2 mutations might be associated with TE in a large cohort of children with CH, expanding the role of a dual oxidase glycoprotein and a member of the NADPH oxidase family in not only affecting classic thyroid hormonogenesis but also disturbing thyroid development. Based on WES and Sanger sequencing analyses, we verified that P138L, G201E, L264CfsX57, D506N, P609S, M650T, H678R, R701Q, A728T, M822V, E810X, S965SfsX29, P982A, E1017G, and S1067L mutations cosegregate with the CHTE phenotype.
Ectopia is one of the TD subtypes characterized by the mislocalization of one or both thyroid lobes. Based on the mouse model, the single candidate gene for TE is Foxe1 because its disruption coincides with a thyroid phenotype that varies between agenesis and ectopy (7). However, we did not observe any mutations in FOXE1 or in classic genes related to TDs, such as TSHR, HHEX, PAX8, NKX2-1, and NKX2-5. Therefore, we performed WES in an attempt to identify candidate genes associated with TE. In our cohort of 268 TD patients, only 134 present with TE (;50%). This frequency is equivalent to those in other studies (48% to 61%) (2). We additionally screened 41 children with CHTE on regular follow-up, strengthening clinicalmolecular correlations.
Our finding regarding DUOX2 is in line with the recently reported SLC26A4 (Pendrin) variations causing CH associated with hypoplasia and agenesis in segregation with a moderate to severe hearing loss phenotype (19) . Moreover, it has been shown the presence of variations in DUOX2 in patients with agenesis (22) , diminished thyroid size (23) , and resistance to thyrotropin (24) , suggesting an additional dual role of DUOX2 besides TH.
Szinnai et al. detected basal expression of DUOX2 at the seventh gestational week, which was the first time point d Total number of patients with serine 1067 successfully covered by Sanger sequencing was 38. Despite several tentative and PCR protocol adaptations, we were not able to amplify serine 1067 from the remaining six patients. analyzed by the authors (25) . Thyroid migration in humans starts at approximately at embryonic day (ED) 24 (2) . Besides, DUOX2 expression did not vary throughout embryogenesis, even 4 weeks before functional differentiation and the beginning of thyroid hormone synthesis (ED70). Interestingly, this stage coincides with the disappearance of the thyroglossal duct that occurs between ED30 and ED40 (gestational week 7.5 to 10) and completes around ED45 to ED70 (2) . The time point of gene expression during human thyroid development appears to be different from that in mouse and zebrafish models (26, 27) . The DUOX2 gene encodes for the enzyme responsible for catalyzing H 2 O 2 production at the apical membrane of thyrocytes, which is necessary for iodination of tyrosine residues of thyroglobulin. DUOX2 is highly expressed in thyroid and salivary glands, followed by the gastrointestinal tract, respiratory epithelia, and breast tissue (28, 29) . In the thyroid, DUOX2 expression is regulated by hormones and transcription factors involved in thyroid organogenesis (30) . In the mouse, the differentiation occurs around ED15.5, after complete thyroid migration (26) . In zebrafish, the detection of thyroid differentiation markers, such as tg, slc5a5, tshr, and iyd, occurs during budding, whereas folliculogenesis occurs ;55 hours postfertilization (hpf) (27) . The duoxa expression starts at 55 hpf, followed by duox at 60 to 80 hpf, with concomitant expression of duox/duoxa only after 80 hpf (27) . This stage corresponds to the onset of hormonogenesis, even though its expression in developmental stage assays always results in lower levels (27) .
Because TH accounts for 15% to 20% of CH cases and may overlap with TD with hypothyroidism, we examined variations in other genes linked to hormonogenesis, such as SLC5A5, TPO, SLC26A4, DUOX1, DUOXA2, and TG (5). To date, no mutation in DUOX1 has been found in patients with CH, and mice deficient in Duox1 lack the CH phenotype (31) .
To investigate whether this finding was a random event, we performed Sanger sequencing of DUOX2 in another 40 children with TE and a single index case whose seconddegree cousin also presented with ectopia. All patients presented with high TSH at the time of neonatal screening and additional confirmatory tests for CH. We identified several coding (seven new for CH) and intronic variants (Fig. 1, Tables 1 and 2 ). Of note, the new variants were located in the N-terminal part of the protein, including ectodomain (G201E, L264CfsX57), first transmembrane domain (P609S), and intracellular loop containing the calcium-sensitive region of DUOX2 (M650T, E810X, M822V, E1017G). The N-terminal domain, which differentiates the DUOXs enzymes from the other NADPH oxidases, does not contain the catalytic core of the protein.
All seven new variants are located in highly conserved residues, as observed through the ClustalOmega alignment depicted in Fig. 1 . Moreover, these variants have MAF #0.01, except E1017G (Table 2 ). Other DUOX2 variants (D506N, H678R, R701Q, A728T, S965SfsX29, P982A, and S1067L) were previously reported in patients with permanent, transient, and subclinical hypothyroidism (20) . Nevertheless, some of the variants (P138L, H678R, R701Q, P982A, E1017G, S1067L) are very common in the control population (Table 2) . Recently, Tan et al. reported a high frequency of the variants P138L, H678R, and S1067L in patients with CH in comparison with a healthy population (32) . They also pointed out the presence of biallelic and monoallelic mutations with no specific clinical association, suggesting the presence of other factors driving this variability (32) . Eleven of 15 DUOX2 variants found in CHTE are considered deleterious in at least one prediction program (G201E, D506N, P609S, M650T, H678R, R701Q, A728T, E810X, P982A, E1017G, S1067L) ( Table 2) .
Functional analysis showed that the variations G201E, L264CfsX57, and E810X impaired both cell surface targeting and H 2 O 2 -generating activity of DUOX2. In contrast, no in vitro evidence for a deleterious effect was found for P609S, M650T, A728T, and M822V mutants. Unfortunately, we were not able to generate the E1017G variant, precluding its functional analysis. Nonsense variations L264CfsX57 and E810X led to truncated proteins lacking the catalytic NADPH oxidase domain and the absence of activity, as expected. The missense mutation G201E caused the suppression of a shift in the electrophoretic mobility of mutant DUOX2 under nonreducing conditions [ Fig. 2(b) ]. It has been previously shown that this change results from the existence of an intramolecular disulfide bridge involving two cysteine residues, which are located in DUOX2 N-terminal ectodomain and extracellular loop. This disulfide bridge is a key event in the trafficking of DUOX2/DUOXA2 that promotes an appropriate conformation of the N-terminal region, which is essential for the subsequent covalent interaction with the maturation factor DUOXA2 (16, 21) [ Fig. 3(d) ]. This oxidative folding of DUOX2 is necessary for both the stability and the function of DUOXA2, as has been previously observed with two other DUOX2 mutants (Q36H and R376W) (15) .
To the best of our knowledge, ;25 DUOX2 mutations in the ectodomain and the first intracellular segment, which contains the calcium responsive sites, have been reported in patients with CH and reduce or abrogate DUOX2 activity (Supplemental Fig. 1) (20) .
Unlike what was previously shown, we did not observe any alterations in DUOX2/DUOXA2 complex expression or H 2 O 2 production with the A728T DUOX2 . This result may reflect the different methods used to measure enzymatic activity, which included initial velocity in this study as opposed to accumulation of H 2 O 2 in the medium. The ectopic location is a result of arrested migration. For instance, DUOX2 localizes to the leading edge of migrating cells in the lung, augmenting motility and wound healing (34) . Duox1 and Duox2 are also needed for mesenchymal cell migration through activation of the phosphoinositide 3-kinase pathway and protein kinase B (35) . Recently, it was demonstrated that Duox2 is a downstream target of FoxE1 in rat thyroid follicular cells (PCCl3) (36) . In addition to its role in thyroid hormonogenesis, DUOX2 may also provide H 2 O 2 for thyroid cell migration. Whereas CHTE could be explained by an alteration of DUOX2-mediated H 2 O 2 , the lack of a disturbance effect on H 2 O 2 production of P609S, M650T, and M822V on DUOX2 activity and therefore on TPO activity suggests that the N-terminal domain may play an additional role in thyroid development through interactions with other proteins not yet identified.
Recently, Hurd et al. (37) demonstrated that the duox mutation could cause dysgenesis in Drosophila, characterized by altered wings with upward or downward curvature or cupping. Moreover, there is evidence in insects, sea urchins, and worms that the primary purpose of duox activity is to enable tyrosine residue crosslinking, which contributes to the formation of extracellular structures (38) (39) (40) in addition to cuticle formation in Drosophila (37).
We still have to consider the possibility of unknown DUOX2 players with morphogenetic roles besides DUOXA2. We suggest that DUOX2 may play a role in human thyroid organogenesis, based on evidence associated with wing dysgenesis in Drosophila (37, 41) and the fact that DUOX2 expression is constant, together with other thyroid transcriptional factors such as NKX2-1, PAX8, and FOXE1, present at the seventh gestational week (27) . Later in thyroid development, as TPO, SLC5A5, and TG expression increase, DUOX2 may undertake the so-called thyroxisome classic function.
Our data reinforce the utility of WES to elucidate the genetic etiology of complex phenotypes and unveil a possible role of DUOX2 in CHTE. These findings were unexpected, based on the primary function of DUOX2 reported in the literature, and clearly need to be confirmed in other TE cohorts and animal models.
